Posts

Tezepelumab vs. Dupilumab in Severe Asthma: Head-to-Head Real-World Data Shows No Clear Winner

Omalizumab Helps High-Risk Patients Tolerate Honeybee Venom Allergy Shots

Dupilumab-Induced Eosinophilia (DIBE) in CRSwNP Affected 48% of Patients

Why Some Chronic Hives Patients May Not Respond Well to Omalizumab: New Biopredictors Identified

Chronic Urticaria: Making Breakthroughs if Managing a Challenging Disease

Hope for Some Alpha-Gal Patients: In-home Graded Protocol

Are These New Biologics Game-Changers or Just More of the Same?

The Esophagus: Not Just a Tube, But a Smart Immune Organ

Artificial intelligence in Allergy and Immunology - JACI review

Staph Aureus on the Skin Associated With Severe Food Allergic Reactions Via a Cascade: IL-33, IL-3, IL-4

Predicting Outcomes in Common Variable Immunodeficiency (CVID)

New Risk Score Predicts Nasal Polyp Recurrence After Sinus Surgery for CRSwNP

Oral ITK Inhibitor Soquelitinib in Development for Atopic Dermatitis

Monoclonal Antibody Targeting OX40L (Amlitelimab) In Development for Atopic Dermatitis

EoE Pipeline Update: Dupilumab Leads, But Exciting Contenders Are Closing In

I-SEE the Future: New Tool (I-SEE index) Changes How We Manage Eosinophilic Esophagitis (EoE)

Once-yearly local therapy for EoE: Long-acting, injectable fluticasone in development for treating eosinophilic esophagitis (EoE)

Twice-a-Year Relief: Depemokimab Poised to Transform Nasal Polyps Care

New HAE Trials and Therapies on the Horizon as of 2026

EU Greenlights Dawnzera™: RNA Therapy for Hereditary Angioedema, Following US Approval